Lonza develops its capacity for virale products

The building of a new cGMP Reinraums will extend large-scale projects in the range of the viralen vaccines as well as the gene therapy unterst�tzenLonza will their virus-based Therapeutik business by the building of a new, ultramodern cGMP Reinraums in their plants in Houston, already existing, Texas. With the new pure area customers can access on capacities in the large yardstick to the support of late stage projects within the range of the viralen vaccines as well as the gene therapy. The pure area will use one-way process systems and production as well as the Fill and of finish enterprises of up to 2000 litres to support will be able. Extended European Union-conformal Fill and finish capacities pushes with fan mA and Biotechkunden of Lonza on large demand. Since this extension makes the simultaneous enterprise of several cGMP expirations possible, the waiting periods of the Lonza customers for pure space capacities will substantially shorten. � we are pleased about the increasing possibilities, which we see, said within the range of the viralen vaccines and the viralen vectors � to David Enloe, director/conductor of the department for virus-based Therapeutik with Lonza. � this investment supports our efforts to take in this exciting area of the new Therapeutika and vaccines a prominent position �. The building and the validation of the new viralen capacities of Lonza will be presumably at the beginning of the yearly 2012 final. Today virale vaccines are examined in detail for the treatment by infections such as AIDS, flu and malaria. The attainable volumes as well as the associated costs for the production of viral supplied vaccines � contrary to traditional egg-based vaccines � make this field of activity an attractive, alternative production beginning. The viral supplied gene therapy represents likewise an increasing market, in which many projects are at present for the treatment of cancer, diseases of the central nervous system (e.g. Parkinson and Huntington) and eye diseases like for example advanced Makuladegeneration in the development stage. Lonza has a broad experience of the pr�klinischen range up to the cGMP production of different viraler products in the commercial yardstick. Likewise the Lonza team brings for viral based Therapeutik one over 15-j�hrige to experience also in the ranges process development, development of analytic samples, validation, full-scale enlargement, cGMP production, product storage and selling. With its specific expertise within the range of the official editions for virale products Lonza helps the customer also to advance their projects within the range of the viralen vectors and vaccines. Lonza is in August 2010 by the acquisition of Vivante GMP Solutions, Inc. entered the business of the virus-based products. The business for virus basierteTherapeutik belongs to the Lonza division Bioscience. Lonza ranks among the offerers of products and services for fan mA, health and Life Sciences industries, leading world-wide, and is able to accompany their customers of the research stage up to final production with their solutions. She is world market leader in production and process company of pharmaceutical active substances, both in the chemical and in the biotechnological range. Bio pharmaceuticals belong to the most important drives behind expansion of fan mA and biotechnology industry. Lonza has an excellent know-how in the production of large and small molecules, Peptiden, amino acids and in the niche production of bio products, which play an important role with the development of new drugs and health products. Likewise a prominent position occupies Lonza in the cellbased research, in Endotoxin Nachweissystemen as well as in the production of products for the cell therapy. Besides the enterprise is prominent Anbieterin of high-quality chemical and biotechnological intermediate products for the markets nutrition, hygiene, water and wood treatment, Agro and hygiene.�

This text was translated automatically.